Supporting new vaccine introduction decisions: lessons learned from the Hib Initiative experience

Vaccine. 2010 Oct 8;28(43):7123-9. doi: 10.1016/j.vaccine.2010.07.028. Epub 2010 Jul 24.


The introduction of Haemophilus influenzae type b (Hib) vaccine in developing countries has suffered from a long delay. Between 2005 and 2009, a surge in Hib vaccine adoption took place, particularly among GAVI-eligible countries. Several factors contributed to the increase in Hib vaccine adoption, including support provided by the Hib Initiative, a project funded by the GAVI Alliance in 2005 to accelerate evidence-informed decisions for use of Hib vaccine. This paper reviews the strategy adopted by the Hib Initiative and the lessons learned in the process, which provide a useful model to accelerate uptake of other new vaccines.

MeSH terms

  • Bacterial Capsules / administration & dosage*
  • Developing Countries
  • Haemophilus Infections / prevention & control*
  • Haemophilus Vaccines / administration & dosage*
  • Humans
  • Immunization Programs / organization & administration*
  • Public-Private Sector Partnerships


  • Haemophilus Vaccines
  • Haemophilus influenzae type b polysaccharide vaccine